Monjuvi
Monjuvi ingredients
| Active ingredient | Strength |
|---|---|
| Tafasitamab | 200 mg/5mL |
What Monjuvi is used for
The FDA lists the approved uses on the official label (below). In the EU, tafasitamab is approved as Minjuvi for:
Minjuvi is indicated in combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Monjuvi
- Generic name
- Tafasitamab-cxix
- Made by
- Incyte Corporation
- Forms
- Injection, Powder, Lyophilized, For Solution
- Given
- Intravenous
- FDA approval
- Biologic licence (BLA) BLA761163
- On the US market since
- 2020
Official information
- Monjuvi prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Tafasitamab-cxix)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Monjuvi?
Monjuvi (Tafasitamab-cxix) is a cancer medicine made by Incyte Corporation, approved by the US FDA.
What are the ingredients of Monjuvi?
Monjuvi contains Tafasitamab (200 mg/5mL).
Is Monjuvi approved in Europe?
The same active substance is approved in the EU as Minjuvi.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA